Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

Real-World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review

    Research output: Contribution to journalReviewResearchpeer-review

  2. The red blood cell count and the erythrocyte sedimentation rate in the diagnosis of polycythaemia vera

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Heterozygous loss of Srp72 in mice is not associated with major hematological phenotypes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Addressing the room for improvement in management of acute promyelocytic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Kathrine Aarup
  • Emelie Curovic Rotbain
  • Lisbeth Enggaard
  • Robert Schou Pedersen
  • Olav Jonas Bergmann
  • Rasmus Heje Thomsen
  • Mikael Frederiksen
  • Henrik Frederiksen
  • Tine Nielsen
  • Ilse Christiansen
  • Michael Asger Andersen
  • Carsten Utoft Niemann
View graph of relations

Ibrutinib has now been approved for treatment of chronic lymphocytic leukemia (CLL) in both front-line setting and as later-line treatment. However, knowledge about the outcomes and adverse events (AE) among patients at a population-based level is still limited. Objectives: To report outcomes and AEs in a population-based cohort treated with ibrutinib outside clinical trials. Methods: We conducted a multicenter, retrospective cohort study including all patients with CLL treated with ibrutinib. Results: In total, 205 patients were included of whom 39 (19%) were treatment-naïve. The median follow-up was 21.4 months (interquartile range (IQR), 11.9,32.8), the estimated overall survival at 12 months was 88.8% (95% confidence interval (CI); 84.3%, 93.3%), and the estimated progression-free survival at 12 months was 86.3% (95% CI; 81.3%, 91.2%). During follow-up, 200 (97.6%) patients had at least one AE and 100 (48.8%) patients had at least one grade ≥3 AE. Eighty-six patients (42.0%) discontinued ibrutinib, hereof 47 (54.7%) due to AEs and 19 (22.1%) had progression of CLL or Richter transformation. Conclusions: In our study, we find comparable, though slightly inferior, overall, and progression-free survival, and discontinuation due to toxicity was higher compared with clinical trials. Patient training and information may improve treatment adherence outside clinical trials.

Original languageEnglish
JournalEuropean Journal of Haematology
Issue number5
Pages (from-to)646-654
Number of pages9
Publication statusPublished - 1 Nov 2020

Bibliographical note

© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

    Research areas

  • chronic lymphocytic leukemia, epidemiology, targeted therapy

ID: 60720386